| Literature DB >> 21544180 |
Abstract
Present study shows that non-covalent interaction of kaouthiotoxin (KTX) with their respective pohospholipase A(2) (PLA(2)) from the venom of N. kaouthia displayed marked synergism to exert cytotoxicity without altering the biochemical properties of PLA(2). For example, although NK-PLA(2) or KTX alone did not induce appreciable hemolysis of washed human erythrocytes; however, the hemolytic potency of NK-PLA(2): KTX complex was significantly higher. Identically, selective lysis of virus infected Sf9 and normal Tn insect cells was further enhanced by the cognate NK-PLA(2): KTX complex as compared to individual components of the complex. Gas-chromatographic analysis of fatty acids released from intact erythrocytes by cytotoxic action of individual NK-PLA(2) and NK-PLA(2): KTX complex demonstrated that ratio between saturated fatty acids (SFA) and unsaturated FA (UFA) was increasing with time of hydrolysis of RBC either in the case of NK-PLA(2) or NK-PLA(2)-KTX complex suggesting NK-PLA(2)-KTX complex apparently displayed the more preference for glycerophospholipids with SFAs on the sn-2 position. Therefore, it may be suggested that KTX first destabilize the target cell membrane followed by higher enzymatic activity of PLA(2) on dislocated and disorganized phospholipid bilayers resulting in a significantly higher (p < 0.05) membrane damage by NK-PLA(2)-KTX complex compared to individual components of the complex.Entities:
Keywords: Cytotoxicity; Naja kaouthia; cobra venom; kaouthiotoxins; phospholipase A2; protein-protein interaction
Year: 2010 PMID: 21544180 PMCID: PMC3086192
Source DB: PubMed Journal: J Venom Res
Figure 1.15% (w/v) SDS-PAGE gel of crude N. kaouthia venom, reconstituted (gel filtration fraction) NK-PLA2: KTX-A complex, and purified venom proteins (KTX-A and KTX-B) under reduced (A) and non-reduced (B) conditions. A. Lane 1, molecular weight markers: phosphorylase b (97,400Da), bovine serum albumin (66,000 Da), ovalbumin (43,000Da), carbonic anhydrase (29,000Da), and lysozyme (14,300Da); Lane 2, reduced crude N. kaouthia venom (50μg); Lane 3, reduced fraction of reconstituted NK-PLA2A: KTX-A complex (30μg); Lane 4, reduced fraction of reconstituted NK-PLA2B: KTX-B complex (30μg); Lane 5, reduced NK-PLA2 A (30μg); Lane 6, reduced NK-PLA2 B (30μg); Lane 7, reduced KTX-A (30μg). B. Lane 1, non-reduced crude N. kaouthia venom (50μg); Lane 2, non-reduced KTX-A (10μg); Lane 3, non-reduced reconstituted NK-PLA2 A:KTX-A complex (10μg); Lane 4, non-reduced NK-PLA2 A (10μg).
Pharmacological properties of NK-PLA2-A, NK-PLA2-B, KTX-A, KTX-B and PLA2-KTX complexes. Values are mean ± SD of four experiments. Values in the same row within each experiment followed by different superscripts are significantly different (P<0.05).
| Properties | Control | PLA2-A | KTX-A | PLA2-A: KTX-A | PLA2-B | KTX-B | PLA2-B: KTX-B |
|---|---|---|---|---|---|---|---|
| Anticoagulant activity1 | 87 ± 3.0 | 99 ± 4.0 | 89 ± 3.0 | 99 ± 3.0 | 100 ± 5.0 | 90 ± 3.0 | 99 ± 4.0 |
| Antibacterial activity2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cytotoxicity3 | |||||||
| (a) VERO | 0.3 ± 0.08 | 1.3 ± 0.2 | 0.8 ± 0.1 | 8.2 ± 0.3 | 1.0 ± 0.1 | 0.6 ± 0.1 | 6.8 ± 0.6 |
| (b) Sf9 (n) | 0.8 ± 0.1 | 4.9 ± 0.5 | 1.1 ± 0.1 | 12.2 ± 1.3 | 3.8 ± 0.4 | 0.9 ± 0.1 | 10.2 ± 1.1 |
| (c) SF9 (in) | 2.5 ± 0.1 | 8.1 ± 0.6 | 3.3 ± 0.4 | 20.1 ± 0.8 | 6.9 ± 0.4 | 3.9 ± 0.4 | 18.5 ± 1.3 |
| (d) Tn (n) | 1.8 ± 0.2 | 7.9 ± 0.5 | 4.8 ± 0.3 | 21.0 ± 1.1 | 6.6 ± 0.5 | 4.1 ± 0.3 | 20.2 ± 1.2 |
| Direct hemolysis4 (time in min) | |||||||
| 30 | 0 | 0 | 0 | 1.5 ± 0.5 | 0 | O | 1.0 ± 0.04 |
| 60 | 0 | 0.21 ± 0.02 | 0.11 ± 0.01 | 6.3 ± 1.1 | 0 | 0.1 ± 0.01 | 4.1 ± 0.1 |
| 90 | 0.1 | 0.73 ± 0.01 | 0.45 ± 0.02 | 14.3 ± 2.1 | 0 | 0.41 ± 0.02 | 13.2 ± 1.3 |
| 120 | 0.2 | 3.3 ± 0.2 | 1.5 ± 0.1 | 32.0 ± 3.4 | 0.4 ± 0.03e | 1.4 ± 0.1 | 29.1 ± 2.1 |
aPlasma Ca-clotting time in seconds caused by 4.0μM PLA2/KTX/PLA2-KTX complex.
bPost 12hr incubation with NK-PLA2 / KTX / PLA2-KTX at a concentration of 500μM
cPercent of cell death post 3hr treatment with NK-PLA2/KTX/PLA2-KTX at a concentration of 250nM.
dPercent of hemoglobin released from 5% (v/v) RBC suspension post incubation for indicated time period by 250nM PLA2/KTX/PLA2-KTX complex post 60min incubation at 37°C. Cent-percent hemolysis was achieved by adding 1% (v/v) Triton X-100 to RBC suspension.
Percent of erythrocyte phospholipids hydrolysis by individual NK-PLA2s, KTXs and NK-PLA2-KTX complexes at a final concentration of 250nM. Values are mean ± SD of four experiments. Values in the same row within each experiment followed by different superscripts are significantly different (P<0.05).
| Incubation time (min) | PLA2-A | KTX-A | PLA2-A: KTX-A | PLA2-B | KTX-B | PLA2-B: KTX-B |
|---|---|---|---|---|---|---|
| 30 | 0a | 0a | 3.8 ± 0.3b | 0a | 0a | 1.3 ± 0.1c |
| 60 | 0.34 ± 0.01a | 0.12 ± 0.01b | 7.3 ± 1.2c | 0.11 ± 0.01b | 0a | 5.2 ± 0.3e |
| 90 | 0.91 ± 0.01a | 0.15 ± 0.02b | 21.0 ± 1.9c | 0.34 ± 0.02b | 0.15 ± 0.01d | 15.1 ± 1.0e |
| 120 | 4.8 ± 0.3a | 0.32 ± 0.1b | 35.2 ± 2.1c | 1.0 ± 0.01b | 0.22 ± 0.02d | 31.2 ± 1.8c |
Figure 2.Analysis of free fatty acid (FFA) released pattern from intact human erythrocytes by individual NK-PLA2, KTX or NK-PLA2: KTX complex. Released FFAs were separated by thin layer chromatography and their methylated esters were analyzed by GC-MS. Values are mean ±SD of three individual experiments.